Skip to main content
. 2022 Nov 11;16(12):639–650. doi: 10.1161/CIRCEP.123.012567

Figure 1.

Figure 1.

Study design. ReVeRA (Reduction of Ventricular Rate in Patients with Atrial Fibrillation) phase 2, multicenter, randomized, double-blind, placebo-controlled study for evaluating the efficacy and safety of etripamil nasal spray (NS) administered intranasally to patients presenting to an emergency department (ED) with atrial fibrillation-rapid ventricular rate (AF-RVR). BP indicates blood pressure; bpm, beats per minute; HR, heart rate.